drugset

drugset / Trial / NCT05868499

Rollover Study From EXG-US-01

NCT05868499 ↗

Phase 1 Enrolling by invitation 12 enrolled Elixirgen Therapeutics, Inc.

NaSingle-groupOpen-labelSupportive care

Summary

This is a long-term rollover follow-up study for Phase I/II study (Protocol EXG-US-01).

Timeline

Start: 2024-01-01
Primary completion: 2027-01-30
Completion: 2027-01-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	EXG34217	Cell therapy	—	—

Indications